Description
BMS-1001 is a potent inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) (IC50 = 2.25 nM). BMS-1001 is capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes
BMS-1001 is a potent inhibitor of the interaction between programmed death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) (IC50 = 2.25 nM). BMS-1001 is capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes
B2758 | BMS-1001 free base DataSheet
Alternate Name/Synonyms: BMS1001,(2-((3-Cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine
Appearance: Crystalline solid
Formulation:
CAS Number: 2113650-03-4
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₃₅H₃₄N₂O₇
Molecular Weight: 594.66
Cell-Permeable?: TRUE
Purity: ≥98%
Solubilities: DMSO
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A potent PD-1/PD-L1 interaction inhibitor
MDL Number:
PubChem CID: 131839624
SMILES: OC[C@H](C(O)=O)NCC1=CC(C)=C(OCC2=CC=CC(C3=CC=C4OCCOC4=C3)=C2C)C=C1OCC5=CC=CC(C#N)=C5
InChi: InChI=1S/C35H34N2O7/c1-22-13-28(18-37-30(19-38)35(39)40)33(43-20-25-6-3-5-24(14-25)17-36)16-32(22)44-21-27-7-4-8-29(23(27)2)26-9-10-31-34(15-26)42-12-11-41-31/h3-10,13-16,30,37-38H,11-12,18-21H2,1-2H3,(H,39,40)/t30-/m1/s1
InChi Key: UWNXGZKSIKQKAH-SSEXGKCCSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |